The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 28, 2023
Filed:
Mar. 27, 2020
Applicant:
Navidea Biopharmaceuticals, Inc., Dublin, OH (US);
Inventor:
David A. Ralph, Columbus, OH (US);
Assignee:
Navidea Biopharmaceuticals, Inc., Dublin, OH (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/61 (2017.01); A61K 31/704 (2006.01); A61K 31/337 (2006.01); A61P 35/00 (2006.01); A61K 31/517 (2006.01); A61K 31/675 (2006.01); A61K 33/34 (2006.01); A61K 31/7068 (2006.01);
U.S. Cl.
CPC ...
A61K 47/61 (2017.08); A61K 31/337 (2013.01); A61K 31/517 (2013.01); A61K 31/675 (2013.01); A61K 31/704 (2013.01); A61K 31/7068 (2013.01); A61K 33/34 (2013.01); A61P 35/00 (2018.01);
Abstract
Disclosed are methods and compositions for repolarizing a tumor associated macrophage (TAM) from M2 to M1 comprising administering to a subject in need thereof an effective dose of a compound comprising a dextran backbone and one or more CD206 targeting moieties conjugated thereto. In certain aspects, the compound further comprises a therapeutic agent selected from: paclitaxel, gemcitabine, lapatinib, and doxorubicin. In further aspect, the therapeutic agent comprises a chelator and at least one metal ion. In certain implementations, the at least one metal ion comprises at least one Cu(II) ions.